Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2023

Baroness Merron Excerpts

Tuesday 6th February 2024 Grand Committee

Just to return to my opening remarks, I am somewhat concerned, and I think we should all be concerned, about, over the years, the size of the body of law we are going to build up for really quite small regulatory matters. Particularly if we end up, frankly, with our device and the EU standards being identical, we will end up with a large body of law to do very little. I know it is not something the Minister can control, but I feel it is worth putting on the record each time we come across a statutory instrument in this area.

[Baroness Merron (Lab)]

My Lords, I also thank the Minister for setting out the provisions in the regulations and for trying to unravel the many pages before us. This seems to be one of those innocuous measures that are needed just because that is where we are, but I very much take on board the comments of the noble Lord, Lord Allan, which are worth wider government consideration.

Clearly, these regulations are needed to support the implementation of new EU regulations that came into operation in Northern Ireland in May last year. They are important in that we have to secure continuity of supply and trade in medical devices within the UK and the EU, and the draft regulations affect a diverse range of equipment and systems to examine specimens in vitro, including items such as blood grouping reagents, pregnancy test kits and hepatitis B test kits, to give just a few examples.

As the noble Baroness, Lady Finlay, said, it is important that we support innovation. The medtech sector provides a huge contribution to our health service and our vibrant life sciences sector, from catching killer diseases early all the way through to preventing infections. The products we are talking about are found in doctors’ surgeries, hospitals and our own homes. They are part of our daily lives. We certainly know from the pandemic how difficult it can be to replace them if supply is disrupted, so we are here to ensure that supply disruption does not happen.

As has been said, the Explanatory Memorandum sets out that these regulations should affect only some 19 businesses in Northern Ireland and cost less than £5 million to implement, but it is important to acknowledge and put on record that they are a valuable part of the UK medtech ecosystem. On these Benches, we certainly support the regulations, which we believe will secure unfettered access to the British market for Northern Ireland businesses and ensure continuity of supply.

I also have a few questions that I hope will be helpful for the Minister. It is welcome that the previous fee structure is being retained to reduce disruption for Northern Ireland operators, but could he say what assessment has been made of any impact on the MHRA’s responsibilities as a regulator? Could he also confirm that it will be resourced to fulfil those responsibilities?

Previously, Ministers have talked about future realignment of regulations on medical devices following our departure from the EU, including consideration of alternate routes to the British market. Can the Minister say a bit more about what opportunities there might be in this area? What is the timeline for the future regulatory regime that the Government want to bring into force? As the Government have not yet set out their proposals, is there a timeline for doing so?

I note that medical devices did not receive attention in the Windsor deal, which was understandably disappointing to some suppliers, which cited the complexity of navigating the current system. Is the Minister considering adding other product classes, such as other devices, to its scope? Will he also clarify the status of devices on which a conformity assessment has been performed by a UK notified body? Following on from the questions from the noble Lord, Lord Allan, in this regard, will it be possible to place devices bearing a “CE” conformity mark, as well as the EU Northern Ireland mark, on to the EU market? Is it the case that no UK notified body has been appointed? If that is the case, when will this be dealt with and what is the delay down to?

In summary, we are pleased to support these amendments to the regulations to secure continuity of supply for the critical medtech sector. I look forward to hearing the Minister’s response.

[Lord Markham (Con)]

I thank noble Lords for their contributions and the spirit in which they were made in terms of helpfulness and trying to make the market as open and productive as possible.

I shall try to answer the questions in turn. To the noble Baroness, Lady Finlay, I say, yes, this is part of the four SIs.

On the noble Baroness’s whole question about making the UK market attractive to innovation, that is exactly what this is all about. On her point about clinical trials, my understanding is that there was a period when we slipped down the league on timings. I am told that a lot of that was because we were trying to prioritise Covid issues but, as I understand it today, we are now back within the timeframes. While we slipped down to 10th place in the league, the understanding from recent business coming in is that we think that we are making our way back up into the champions league spots, for want of a better phrase. I am assured that we have seen quite an improvement in the time taken in clinical trials.

On the noble Baroness’s question about what this means for the MHRA—the noble Baroness, Lady Merron, asked a similar question—we do not believe that this should have a significant impact. At the same time, I am totally with the sentiment that we do not want the MHRA to be a bottleneck, not just in this area but generally because speed to market is important here. In the last Budget, we agreed quite an increase in the MHRA’s budget, exactly so that it is able to pass such things through more quickly.

On the points about mutual recognition, it is absolutely our direction of travel. We are looking to do that with other authorities. Again—this also goes to the question of the noble Lord, Lord Allan—we are recognising the “CE” marks until 2030. That is probably a good example of mutual recognition.

Pharmacy First

Baroness Merron Excerpts

Tuesday 6th February 2024 Lords Chamber

[Baroness Merron (Lab)]

My Lords, I recognise that pharmacies already do far more than just dispense prescriptions and sell items. They are highly trained experts, easily accessible and approachable, with a reach across the entire country. As we saw during the pandemic, they are a highly trusted part of our communities and they are to be commended. But their skills and knowledge are often underutilised, even though pharmacists can take the pressure off GPs and encourage people to seek advice and services that they otherwise might not have sought. That is why we recently announced that we would want to bring NHS out-patient appointments closer to people, and through high street opticians as well.

This announcement will not make up for the 1,000 pharmacies that have closed or the 2,000 GPs that have been cut since 2015. Patients today can be waiting over a month to see a GP, if they can get an appointment at all. When I think back to 2010, I recall that people could get an appointment within 48 hours. Can the Minister update your Lordships’ House on what has happened to the Government’s pledge to deliver 6,000 more GPs this year? What is being done to support community pharmacies, which are already facing a perfect storm with inflationary pressures on running costs, recruitment challenges and an unstable medicines market?

As the Association of Independent Multiple Pharmacies chief exec said, we should not forget that pharmacies are seriously underfunded and that the

“stranglehold of chronic underfunding must be relieved … to ensure our community pharmacies continue to exist and can deliver”

what the Government are expecting. How will the Government ensure that GPs and pharmacies work closely together, given some of the fractured relationships that currently exist over their roles? On delivery, how long will it take to get up to the promised capacity? When will the promised IT systems go fully live across all pharmacies taking part, and how will the public be made aware of the services that they will now be able to get from their local pharmacy?

The Minister will know of concerns regarding the impact on the pharmacy workforce. The concern is that they will just be overwhelmed, which begs the question: why was Pharmacy First not phased in? What is being done to ease the inevitable extra pressure on pharmacies, including in the use of their premises? How will the Government ensure the privacy that we all need? It is not acceptable to be discussing personal matters for all to hear, nor to receive a vaccination that may require the removal or adjustment of clothing for all to see.

Turning to some of the specific services, I note that pharmacists will be able to treat urinary infections, which women suffer frequently, requiring urgent treatment as soon as the signs start to occur. But why is that only up to the age of 64? It is very welcome to get blood pressure checks routinely done at pharmacies, particularly for older people with long-term conditions. At present, many are asked to buy their own assessment machine and report in the results to the surgery, which they cannot do, and not having a blood pressure reading can lead to delays in getting medication. So how will the Government ensure that key data is safely, accurately and speedily exchanged between pharmacies and GPs?

Finally, what is the Government’s plan in the longer term to integrate the increase in independent prescribers, who are being trained as part of the long-term workforce plan? Does the Minister agree that we should accelerate the rollout of independent prescribing to establish a community pharmacist prescribing service, covering a wide range of common conditions? That would support patients with chronic conditions, which is one of the biggest challenges facing the NHS. Does he agree that community pharmacies will have an important role to play in supporting GPs in the management of long-term conditions, such as hypertension and asthma, and in tackling the serious issue of overprescribing, which is responsible for thousands of avoidable hospital admissions every year?

Bringing healthcare into the community means that patients will have greater control and be seen faster, while GPs will be freed up to see more complex cases. From these Benches, we have long argued for a greater role for pharmacists and pharmacies. The NHS should work as a neighbourhood health service as much as a National Health Service, and that is a development to which these Benches are wholly committed.

[Lord Allan of Hallam (LD)]

My Lords, the holy grail for health policy is a change which improves the service for patients at the same time as reducing the cost of delivering that service. I think we can all see the potential for Pharmacy First to be such a move, if executed well. I have a few questions for the Minister and his answers will help us to understand whether he is on the right path in this grail quest.

First, I understand that there will be a payment per consultation, if the consultation meets criteria that the Government have set, but that there will be a cap on the total budget. Can the Minister explain how this cap will work? Is it per pharmacy or per integrated care board, and what happens if it is exceeded? I do not think that we want people going back to more costly channels simply because of an accounting feature. Secondly, can he explain how the Government will assess value for money in comparing the cost of the Pharmacy First consultations with the estimated savings on the GP and A&E side?

Thirdly, while we are discussing urgent care today, can the Minister also say whether the Government are looking at using pharmacies for approving repeat prescriptions—this was raised by the noble Baroness, Lady Merron—for drugs such as statins that people may be on for many years? The current protocol requires them to go back to their GP for regular reviews. Are there any plans afoot to move some of that medicine review process for long-term conditions also into the Pharmacy First programme?

Can the Minister also explain how instructions will be given to NHS 111 services so that they can properly direct people, in light of Pharmacy First now being an available option? It could make a real difference to the pressure on A&E services if 111 moved appropriate cases over to pharmacies. There are concerns that 111 has a natural tendency to be risk averse and refer people to A&E. If we are going to ask it to refer people now to pharmacies, we need to understand how that shift in direction will take place.

Finally, I have a digital question. It is not the one about the joined-up records that we discussed earlier at Oral Questions, as I am confident that the Minister will tell us that the Government are on track for that. What I want to raise is, even when the pharmacy has issued a prescription and dispensed it, at present what happens is that it will then print it off and post it to the NHS Business Services Authority for payment. This happens with all the prescriptions in the pharmacy system at present. My understanding is that the business services authority will then scan them into its system to make the payments—which seems quite farcical in 2024. So I would be interested to hear from the Minister what plans the Government have to get rid of that piece of the equation or to make it more efficient, so that, when a prescribing process happens electronically, it happens all the way through, to the point at which the pharmacy is reimbursed for the work that it has done.

Premature Deaths: Heart and Circulatory Conditions

Baroness Merron Excerpts

Tuesday 6th February 2024 Lords Chamber

Asked by

[Baroness Merron]

To ask His Majesty’s Government what assessment they have made of the increasing numbers of premature deaths from heart and circulatory conditions since 2020.

[The Parliamentary Under-Secretary of State, Department of Health and Social Care (Lord Markham) (Con)]

The Government are committed to reducing premature deaths from cardiovascular disease. The NHS long-term plan aims to prevent 150,000 heart attacks, strokes and dementia cases by 2029, as well as preventing up to 23,000 premature deaths and 50,000 acute admissions over 10 years. The major conditions strategy will look at how best to tackle the key drivers of ill health and increase the healthy years of life for people with major conditions such as cardiovascular disease.

[Baroness Merron (Lab)]

My Lords, the Office for Health Improvement and Disparities reports a persistently high number of excess deaths involving cardiovascular disease since the beginning of the pandemic, avoidably cutting short more than 100,000 lives in England alone. What are the urgent plans for treating the thousands who are waiting for healthcare? How will the Government extend the roles and joined-up working of a range of healthcare professionals beyond GPs to support the millions who are living with an undiagnosed risk of high blood pressure, raised cholesterol, diabetes and obesity?

[Lord Markham (Con)]

I thank the noble Baroness and draw attention to my register of interests: I am a shareholder in a small health company that does high-end heart tests for the private sector.

It is fitting that February is Heart Month. The concern that the noble Baroness raises is exactly the one that noble Lords will have heard me speak about. This is precisely the concern that Chris Whitty, our Chief Medical Officer, was worried about during Covid, with missed appointments because people stopped going to see their doctor meaning that we missed things such as high blood pressure and high cholesterol. To tackle the problem urgently, as the noble Baroness suggests, we have put 7,500 blood pressure checkers in pharmacies. They have done 2 million checks to date. We have sent 270,000 blood pressure monitors to houses and have instigated mid-life NHS health checks to look specifically at early heart indicators so that we can try to tackle the problem that the pandemic caused.

Allied Health Professionals: Prescribing Responsibilities

Baroness Merron Excerpts

Tuesday 6th February 2024 Lords Chamber

[Lord Markham (Con)]

I suspect that we are starting to get on to the debate we will have shortly on physician and anaesthetist associates. In both cases there is definitely a role for them, because we want to support doctors in the surgery and allow them to train and teach at the top of their profession. Clearly, however, we need to be sure of what such people can do and where they need extra supervision, and that is what we are setting out.

[Baroness Merron (Lab)]

My Lords, further to the Minister’s reply to my noble friend Lord Bradley, what is the Government’s plan to increase and integrate the number of independent prescribers being trained as part of the long-term workforce plan? Given that community pharmacists are already trained to vaccinate against Covid-19 and flu, will the Government be expanding the service to include the delivery of MMR jabs, in order to help address recent measles outbreaks?

[Lord Markham (Con)]

First, on the long-term workforce plan, yes, we want to increase the number of allied health professionals by 25% by 2030. We see a lot of that group—some 20%—coming through via apprenticeships. It has been proven just how well pharmacies managed to supplement MMR vaccinations in the Covid and flu space, so it is a good idea. I will need to take that idea back to the department, rather than agreeing to it on the hoof, but I will come back on it because it is an excellent one.

NHS: Fracture Liaison Services

Baroness Merron Excerpts

Monday 5th February 2024 Lords Chamber

[Lord Markham (Con)]

The noble Lord is correct; there has been some good evidence gained. As I mentioned previously, it shows that the probability of suffering from a fracture if you have been in a clinic is 10%—some studies have shown as much as 30% to 40%. It also shows, as my noble friend Lord Black was saying, that there is actually a good cost saving: it is thought that £65 million per annum will give a return of more than £100 million. There are some very good statistics around this, and I assure noble Lords that we are making a strong case for their expansion.

[Baroness Merron (Lab)]

My Lords, the Minister has previously confirmed in your Lordships’ House that just 51% of ICBs have a fracture liaison service, and that the rest of the country has what he described as “different versions of it”. Will he explain what is meant by this, so that it can be understood whether this means a full fracture liaison service or not in the remaining 49%? When will Minister Caulfield’s promise to establish more fracture liaison services actually be delivered?

[Lord Markham (Con)]

I believe that the latest number is 57%, but the general point stands that that leaves 43% which are making other types of provision. The work we are doing right now is trying to understand the success of those versus what we see as prudent with that 57%. That is the case we are making and the case that Minister Caulfield was referring to as well. I believe personally that it is a strong case, so it is something that, as I say, we are looking to work further on.

Maternity Services

Baroness Merron Excerpts

Thursday 25th January 2024 Lords Chamber

[Baroness Merron (Lab)]

My Lords, I congratulate my noble friend Lady Taylor on securing this debate and setting out the issues with her customary elegance and clarity for us to build on further. As my noble friend said, all the briefings we received in preparation for this debate referred to a very worrying situation and—I shall head this off at the pass—to the fact that Covid cannot be used as an excuse because the pressures have been building for more than 10 years, which is something that I am sure the Minister will want to address.

As we heard, despite the Government and the NHS publishing various targets, programmes, strategies and action plans over the years to improve services, and having a lot of different evidence bases to call upon, and, sadly, inquiries into circumstances where things have gone tragically wrong, it is unfortunate that we find that maternity is an example of how services have deteriorated on the Government’s watch. As my noble friend Lady Armstrong said, even with all these plans, targets and so on, without proper implementation, they do not deliver improvement.

Within all of this, we know the data is important. I noticed in his response to a Written Question from the right reverend Prelate the Bishop of St Albans last month, the Minister explained that:

“The most recently published data which measures progress against”


government targets in the national maternity safety ambition

“coincided with the COVID-19 pandemic and is out of date”.

The Minister also said in his written reply that:

“The Department is working to increase the frequency and timeliness of publications”.


I am sure the whole House would agree that that would be welcome.

Does the Minister agree that it is extremely difficult to deal with any issue, including that of maternity services, without knowing the facts of the challenge? This was raised with particular regard to inequalities by my noble friend Lady Thornton and the noble Baroness, Lady Gohir.

The House will be aware of Labour’s commitment to train 10,000 more nurses and midwives every year, along with long-term workforce planning across the NHS by reviewing training and looking at creating new types of health and care professionals, drawing on a diverse skills mix. We are also committed to setting an explicit target to end the maternal mortality gap, which sees black women in the UK four times more likely to die while pregnant, giving birth or as new mothers, compared with white women. This will come partly from the aforementioned training of more midwives and health visitors but also by the incentivising of continuity of care—something referred to by the noble Baroness, Lady Cumberlege, from her experience in chairing the work that gave rise to the Better Births report. It will also come from improving course content on the presentation of illness and pain among different groups. I hope the contributions and expertise in your Lordships’ House will continue to contribute to making those commitments a reality in terms of improvement.

As we have heard a number of times in this debate, the Care Quality Commission has reported a decline in positive maternity experiences in recent years. The noble Lord, Lord Patel, described the health of maternity services as a bellwether for the health of our NHS. As we have heard, it seems that in our maternity services we are now finding that we are well behind in the maternal mortality stakes. That was not the case, but it is now. I was touched, as were other noble Lords, when the noble Lord, Lord Patel, expressed his gratitude to the thousands of mothers who allowed him to be part of their lives. I am sure that those thousands of mothers would also wish to express their gratitude to the noble Lord.

The approximately 20,000 responses to the CQC’s Maternity Survey 2022, which my noble friend Lady Donaghy referred to, showed that fewer women were being given the help they needed when they contacted a midwifery team. They were getting less help in hospital care after birth and less help with postnatal care. It also showed less confidence and trust, and a reduction in the availability of appropriate advice and support when contacting a midwife or hospital at the start of labour or while in the care of that hospital.

I thank, as have other noble Lords, the whole of the staff team who are in the provision of maternity services. As the noble Baroness, Lady Watkins, said, many of these staff go above and beyond. That is confirmed by the CQC, and rightly so. However, it is evident that there are external pressures on them that get in the way of them doing the job they need to do, and it is on this that the Government hold the levers.

The CQC has continued to raise concerns about the quality of maternity care in England over many years. In the most recent State of Care report for 2021-22, the regulator reiterates its ongoing concerns about both the safety and the ethnic inequality of maternity services, as well as the impact of poor training, poor culture and poor risk assessments on people’s care.

By September 2023, the CQC had inspected nearly three-quarters of maternity services and described the overall picture as one of a service and staff under huge pressure, warning that many patients were still not receiving safe and high-quality care. Most recently, in November 2023, around two-thirds of maternity units in England received a CQC rating of “requires improvement” or “inadequate in safety”. That compared with 55% in the previous year, so it is going in the wrong direction. I would be interested to hear the Minister’s response on this.

We have heard much in this debate, and rightly so, about maternal mortality. The latest data shows that between 2020 and 2022 it increased to levels not seen since 2003 to 2005. It is right, as noble Lords have said, that even within this extremely concerning statistic all is not uniform: the case is far worse for women who live in the most deprived areas. They are more than twice as likely to die during pregnancy, or up to one year afterwards, than women living in the least deprived areas. Between 2019 and 2021, 12% of the women who died had severe and multiple disadvantages and, as we have heard, women from black and ethnic backgrounds are three times more likely than white women to die during or up to six weeks after pregnancy, while Asian women are twice as likely.

The noble Baroness, Lady Gohir, was right to say that this broad-brush approach to definition masks the range and depth of inequalities. The noble Baroness, Lady Bull, was also right to point to the fact that inequality extends to those with a learning disability. Can the Minister say whether work is going on to produce much closer attention to the needs of groups, and to break down the nature of people within those groups, in order that we can reflect and respond to the reality of those with differing experience?

We have heard today about the tragedy of many failures within maternity services. I recall, during the many Statements that we have dealt with in this House, the expression of how devastating it is to look at these failures and to have to discuss them. Having looked recently at the independent review of maternity services at Nottingham University Hospitals NHS Trust, which is ongoing, I would say that it is staggering that it required concerned local families, MPs and others over many years to be crying out about the quality and safety of maternity services in their area. This will be the UK’s largest ever maternity services review, with around 1,700 families’ cases reportedly being examined. Donna Ockenden, who is in the lead, has said that the review will not report until September 2025 because

“no one will thank us for doing a half-baked job”.

She added that there would also be a period of family feedback, which could last until the start of 2026. This makes absolute sense, but it is worth asking why it took so long for those investigations to begin.

We have heard so much about staffing: it is absolutely key and retention is what we need. In addition, my noble friend Lady Thornton referred to the multidisciplinary training that is absolutely vital to cement the proper working practices that we need. Yet we find that so many cannot find the time to attend this training. Can the Minister say what is being done to address this?

In conclusion, the birth of a child, as we know, is a unique event. Mothers, babies and families all deserve the best. I hope that this debate and the work that may flow from it will deliver the improvements that we all need to see.

Smoking

Baroness Merron Excerpts

Thursday 25th January 2024 Lords Chamber

[Lord Markham (Con)]

First, my understanding about New Zealand is that one of the biggest bones of contention was that it was looking to reduce the number of smoking retailers from 6,000 to 600; that is where their Bill came into difficulty. I am afraid I must disagree with my noble friend on the importance of this. It costs the economy about £17 billion a year and causes about 80,000 deaths, and 80% of people who have taken up smoking wish that they had never started. I think those are very strong reasons which I know the majority of this House is behind, and that is why I am delighted to be introducing that legislation shortly.

[Baroness Merron (Lab)]

My Lords, it has been reported that the decline in smoking has nearly ground to a halt since the pandemic, with many former smokers lapsing and many more young people now taking up smoking. Now that the smoking cessation drug cytisine is available, what is the Government’s assessment of how its availability will contribute or otherwise to the progress towards the smoke-free ambition by 2030? What plans are there to ensure its availability across the country, particularly among hard-to-reach groups of smokers?

[Lord Markham (Con)]

Hopefully, my previous answer shows that we are investing major money in cessation services. I must admit to not being that familiar with the drug the noble Baroness mentions, so I will follow up in writing to give her the details.

National Immunisation Programme

Baroness Merron Excerpts

Thursday 18th January 2024 Grand Committee

[Baroness Merron (Lab)]

My Lords, I add my congratulations to my noble friend Lady Ritchie, who is as we all agree a great champion for better health through greater take-up and availability of vaccines and immunisation programmes. She rightly described them as a sound investment by the NHS, and I certainly agree.

There are two main issues at play: first, the failure of already approved and recommended drugs to be included in the national immunisation programme and, secondly, the number of factors that have slowed down how long the whole process takes. It potentially takes around a decade to pass through every stage of trial and approval and two years or more for a new vaccine to reach patients post regulatory authorisation.

I am sure that we all want vaccines to be available to patients quicker and to see full account taken of patient safety and cost effectiveness. It seems to me that the way forward is to emphasise systemic options to improve availability without sacrificing the necessary safeguards.

Like other noble Lords, I am grateful to the many stakeholders who have conveyed their views to me on how to accelerate the adoption of new innovative vaccines by the national immunisation programme. Their main suggestions for tackling these damaging delays focus on ensuring that the overall system works better while adapting to additional risk, perhaps in extraordinary circumstances, such as those we saw in the Covid pandemic.

But it bears pointing out that this is against the backdrop of a step in the wrong direction, which we have heard about, such that, due to a decade of declining rates of uptake of the MMR vaccination among preschool children, for example, the UK no longer has the status of having eradicated measles, according to the World Health Organization. This is borne out by Steve Russell, whom the noble Lord, Lord Allan, referred to; he is the chief delivery officer and national director for vaccinations and screening at NHS England. He highlights a decline in vaccination-programme uptake, particularly for childhood vaccinations, in the foreword to the NHS England strategy.

I thank my noble friend Lady Twycross for bringing before us the importance of childhood vaccination. She brought it into focus by sharing her own story, for which I am sure we all thank her, but her call for evidence-based intervention and for ensuring coverage by immunisation programmes surely must be heeded. It would be helpful to hear what discussions continue to take place across government about tackling misinformation and disinformation about MMR and other vaccines, which we obviously still see proliferating on social media.

I will put a few points to the Minister about the much-needed improvement of the UK’s performance in immunisation development and delivery. We heard from my noble friend Lady Ritchie about the GSK-hosted round table, which she kindly chaired. I noticed that she described the response during the Covid-19 pandemic as “remarkable” and I endorse her comments. That response magnified the value of vaccines to individuals, health systems, society and the economy, and it is absolutely vital to embed the lessons that were learned before they are lost, as she said. So I amplify the points made by my noble friend, because it would help to hear from the Minister about what lessons the Government have learned from the pandemic, what assessment they have made of the potential value of each of those lessons and what steps are being taken, at the very least, to assess the potential benefits from continuing in that manner, but ideally to take action to embed in the system all the good practice from which we have learned.

Within this, I echo the call for pharmacies to be complimented for rising to the challenge during the pandemic. They continue to play an increasingly key role in providing advice and healthcare, including convenient and accessible vaccination services. Does the Minister consider that community pharmacies can play an even larger role in immunisation programmes by expanding the range of vaccines that they can offer, including those for shingles, RSV and pneumonia? What steps are being taken to marshal the forces of community pharmacies and expand their potential as community well-being hubs?

The second point is a predictable issue with a bearing not on safety but on bureaucracy. I am aware of the potential complexities, but what steps are the Government taking to explore the adaptation of funding mechanisms to expected new programmes in order to avoid delays and issues because of the constraints of rigid envelopes and complex approval processes? What are the general steps in the areas of improving resourcing, co-ordination and process across regulators and health-technology assessment bodies?

There is an increasing focus on the role of vaccination in fighting AMR. The JCVI has shown some willingness to consider its impact in its value-assessment criteria. I suggest to the Minister that this could be an interesting development. Given that it is newer science, it would be interesting to hear from the Government what assessment they have made of the AMR-reduction benefit from vaccines and whether they are taking any steps to explore how it can be harnessed further.

With further reference to the JCVI, I want to raise the suggestion of evolving its work to better enable the adoption of innovative vaccines. Broadly, it is important that the JCVI is continuously looking ahead. Can the Minister indicate how the Government are working with JCVI to ensure this mode of travel?

I was very interested in the argument put forward by Policy Exchange that a busy pipeline of new vaccine technologies in the coming years, including a growing number of therapeutic as well as preventative candidates, coupled with a concerning decline—as we have discussed —in the uptake of key programmes such as MMR, necessitates a fresh look at the architecture and delivery model for vaccine development and deployment. Policy Exchange’s key recommendations on delivery include boosting ministerial oversight—I am sure the Minister will have a view on that; expanding the role for community pharmacy, which we have talked about many times in our Chamber; creating a new workforce model; and piloting a local delivery model called a “vaccine collaborative”. The positive and overarching principle behind those suggestions is that of extending care further into the community. It would be helpful to get a sense of the Government’s ambition in this area and the steps they are taking to move beyond traditional delivery mechanisms to make this improvement.

As I said at the beginning, we all want an improvement in the UK’s performance in immunisation development and delivery. I look forward to hearing the Minister’s response.

NHS: Drug Shortages

Baroness Merron Excerpts

Wednesday 17th January 2024 Lords Chamber

[Lord Markham (Con)]

My noble friend is correct that this so-called off-label use of these diabetes drugs for weight-loss-type treatments is causing some of the shortages she mentions. That is exactly what we have been tackling, and we have been making sure that the only way you can get the Wegovy weight-loss drug is actually on a very tightly controlled weight management programme normally run through hospitals, and not through normal GPs, exactly to get on top of that issue.

[Baroness Merron (Lab)]

My Lords, there are reports in the media today of pharmacists having to deal with frustrated and worried customers who are faced with shortages of medicines including HRT and the drugs for ADHD, diabetes and cancer. Can the Minister indicate what action is being taken to support and gather feedback from pharmacists who are dealing with such an unsatisfactory situation? What steps are being taken to ensure that, in the future, the supply system is able to cope as soon as demand for medicines increases?

[Lord Markham (Con)]

We find that each one is a different case in point. HRT is an example: we actually saw a 50% increase in demand for it over the last year, so suddenly that is quite a dislocation for the market, and you need to gear up very quickly in terms of the supply chain issues. Strep A was the example last year that we will all be familiar with; normally, it does not come until later in the year, but suddenly there was a very early outbreak in October, which caused the demand there. You find that every single drug tends to be a different case in point. There is a range of tools that they work with; it is working with the NHS, MHRA suppliers and pharmacists, and it is case by case. As I say, sometimes it is the MHRA expediting medicines to get new supply in; sometimes it is working on alternative suppliers; sometimes it is buying internationally—that is what we did in the case of strep A—and sometimes you do have to go as far as the serious shortage protocols, finding substitutes or, in extreme cases, changing doses. There is a range of programmes on it, which by and large are managing to tackle it.

Health: RSV Immunisation

Baroness Merron Excerpts

Wednesday 17th January 2024 Lords Chamber

[Lord Markham (Con)]

A DHSE team is working closely with the NHS, because that needs to be rolled out. Again, it depends on whether we go for the maternal option or do it via a different process with infants. The final answer on that will depend on the groups that are chosen; likewise, vaccinating the over-75s will more likely be in a primary care situation. When we finalise all those things, there will be a very clear plan, but there is a team in DHSE that is responsible and accountable for this.

[Baroness Merron (Lab)]

My Lords, over the past decade, we have seen the take-up of immunisation decrease. Particularly worrying is the great disparity between white Britons receiving the flu vaccine, where coverage is 83.6%, and black Britons at just 52.2%. In anticipating the RSV immunisation programme, how do the Government plan to address vaccine hesitancy, particularly in the black community?

[Lord Markham (Con)]

The noble Baroness is absolutely correct. This applies to the take-up of a whole range of vaccinations—MMR is another example, as is polio. Inner cities, including London and cities in the West Midlands, seem to be examples where take-up is quite a few percentage points lower, not just because of ethnic minorities but more because those areas have larger migrant populations, who often have not been part of the vaccination programme. Specifically to that aim, we are now publishing information in 15 languages and are trying to reach out to some harder-to-reach groups, such as ethnic minorities, the Traveller community and Orthodox Jews. There is a programme for all this, because it is a challenge. We all know that, during Covid, we talked about an R rate of 1.5. Would you believe that, for MMR, it is 13? That is just to give noble Lords an idea. It is very, very infectious.